(AZTA) Azenta - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 941m USD | Total Return: -26.1% in 12m
Avg Turnover: 22.2M
EPS Trend: 79.9%
Qual. Beats: -2
Rev. Trend: -67.0%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -0.1 is critical
Extended 1w
Tailwinds
No distinct edge detected
Azenta, Inc. (AZTA) specializes in sample exploration and management solutions for the global life sciences industry. The company operates two primary divisions: Sample Management Solutions, which provides automated storage, cryogenic systems, and repository services, and Multiomics, which focuses on genomic analysis, gene sequencing, and synthesis services. Formerly known as Brooks Automation, the company rebranded in 2021 to pivot exclusively toward life sciences technology.
The life sciences tools sector relies heavily on the razor-and-blade business model, where the installation of proprietary automated hardware drives recurring revenue through specialized consumables and long-term service contracts. As drug discovery becomes increasingly data-driven, the demand for high-integrity biosample preservation and genomic sequencing continues to scale across pharmaceutical and academic research institutions.
Investors can further evaluate these market dynamics and company valuation metrics on ValueRay. Azenta maintains a global footprint with significant operations in North America, Europe, and the Asia Pacific, supported by strategic initiatives such as space-based scientific experimentation partnerships.
- Life sciences R&D budget cuts reduce demand for automated storage systems
- Multiomics segment revenue growth depends on genomic sequencing and synthesis volume
- China market exposure creates geopolitical risk and regional revenue volatility
- Transition to pure-play life sciences model impacts long-term margin expansion goals
- Capital allocation strategy and share repurchases influence investor confidence and valuation
| Net Income: -178.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.06 > 1.0 |
| NWC/Revenue: 78.75% < 20% (prev 83.63%; Δ -4.88% < -1%) |
| CFO/TA 0.03 > 3% & CFO 61.0m > Net Income -178.2m |
| Net Debt (-324.8m) to EBITDA (49.2m): -6.61 < 3 |
| Current Ratio: 2.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.1m) vs 12m ago 0.72% < -2% |
| Gross Margin: 44.55% > 18% (prev 0.46%; Δ 4.41k% > 0.5%) |
| Asset Turnover: 30.24% > 50% (prev 28.69%; Δ 1.55% > 0%) |
| Interest Coverage Ratio: -0.05 > 6 (EBITDA TTM 49.2m / Interest Expense TTM 142.1m) |
| A: 0.25 (Total Current Assets 727.0m - Total Current Liabilities 257.2m) / Total Assets 1.90b |
| B: 0.65 (Retained Earnings 1.24b / Total Assets 1.90b) |
| C: -0.00 (EBIT TTM -7.61m / Avg Total Assets 1.97b) |
| D: 3.48 (Book Value of Equity 1.22b / Total Liabilities 349.2m) |
| Altman-Z'' = 7.38 = AAA |
| DSRI: 0.86 (Receivables 131.3m/149.5m, Revenue 596.6m/585.8m) |
| GMI: 1.03 (GM 44.55% / 45.87%) |
| AQI: 0.91 (AQ_t 0.50 / AQ_t-1 0.55) |
| SGI: 1.02 (Revenue 596.6m / 585.8m) |
| TATA: -0.13 (NI -178.2m - CFO 61.0m) / TA 1.90b) |
| Beneish M = -3.28 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 20.50 with a total of 957,154 shares traded.
Over the past week, the price has changed by +26.23%,
over one month by -18.49%,
over three months by -25.13% and
over the past year by -26.05%.
Azenta has received a consensus analysts rating of 3.43. Therefore, it is recommended to hold AZTA.
- StrongBuy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 26.2 | 27.8% |
P/E Forward = 29.0698
P/S = 1.5779
P/B = 0.5983
P/EG = 0.5263
Revenue TTM = 596.6m USD
EBIT TTM = -7.61m USD
EBITDA TTM = 49.2m USD
Long Term Debt = unknown (none)
Short Term Debt = 7.78m USD (from shortTermDebt, last fiscal year)
Debt = 55.7m USD (from shortLongTermDebtTotal, last quarter) (leases 55.7m already included)
Net Debt = -324.8m USD (calculated: Debt 55.7m - CCE 380.5m)
Enterprise Value = 616.4m USD (941.2m + Debt 55.7m - CCE 380.5m)
Interest Coverage Ratio = -0.05 (Ebit TTM -7.61m / Interest Expense TTM 142.1m)
EV/FCF = 21.46x (Enterprise Value 616.4m / FCF TTM 28.7m)
FCF Yield = 4.66% (FCF TTM 28.7m / Enterprise Value 616.4m)
FCF Margin = 4.81% (FCF TTM 28.7m / Revenue TTM 596.6m)
Net Margin = -29.86% (Net Income TTM -178.2m / Revenue TTM 596.6m)
Gross Margin = 44.55% ((Revenue TTM 596.6m - Cost of Revenue TTM 330.8m) / Revenue TTM)
Gross Margin QoQ = 42.84% (prev 42.86%)
Tobins Q-Ratio = 0.32 (Enterprise Value 616.4m / Total Assets 1.90b)
Interest Expense / Debt = 255.0% (Interest Expense 142.1m / Debt 55.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -6.01m (EBIT -7.61m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.83 (Total Current Assets 727.0m / Total Current Liabilities 257.2m)
Debt / Equity = 0.04 (Debt 55.7m / totalStockholderEquity, last quarter 1.55b)
Debt / EBITDA = -6.61 (Net Debt -324.8m / EBITDA 49.2m)
Debt / FCF = -11.31 (Net Debt -324.8m / FCF TTM 28.7m)
Total Stockholder Equity = 1.67b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.03% (Net Income -178.2m / Total Assets 1.90b)
RoE = -10.69% (Net Income TTM -178.2m / Total Stockholder Equity 1.67b)
RoCE = -0.46% (EBIT -7.61m / Capital Employed (Total Assets 1.90b - Current Liab 257.2m))
RoIC = -0.47% (negative operating profit) (NOPAT -6.01m / Invested Capital 1.27b)
WACC = 10.41% (E(941.2m)/V(996.9m) * Re(11.03%) + (debt cost/tax rate unavailable))
Discount Rate = 11.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -8.83%
[DCF] Terminal Value 66.75% ; FCFF base≈30.0m ; Y1≈27.5m ; Y5≈24.4m
[DCF] Fair Price = 13.29 (EV 288.0m - Net Debt -324.8m = Equity 612.8m / Shares 46.1m; r=10.41% [WACC]; 5y FCF grow -10.29% → 2.50% )
EPS Correlation: 79.89 | EPS CAGR: 26.21% | SUE: -4.0 | # QB: -2
Revenue Correlation: -66.98 | Revenue CAGR: -3.15% | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=-56.90% | Revisions=-50% | Analysts=5
EPS current Year (2026-09-30): EPS=0.38 | Chg30d=-50.26% | Revisions=-56% | GrowthEPS=-25.9% | GrowthRev=+1.1%
EPS next Year (2027-09-30): EPS=0.61 | Chg30d=-42.97% | Revisions=-33% | GrowthEPS=+62.4% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: -56%